| scholarly article | Q13442814 |
| P50 | author | Anahit Ghochikyan | Q40272584 |
| P2093 | author name string | David H Cribbs | |
| Irina Petrushina | |||
| Michael G Agadjanyan | |||
| Mikayel Mkrtichyan | |||
| Nina Movsesyan | |||
| Adrine Karapetyan | |||
| P2860 | cites work | The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 |
| Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization | Q28185520 | ||
| Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production | Q70338857 | ||
| Dosing in phase II trial of Alzheimer's vaccine suspended | Q73632329 | ||
| QS-21: a water-soluble triterpene glycoside adjuvant | Q94447746 | ||
| Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 | ||
| TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties | Q29547848 | ||
| High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation | Q29616564 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease | Q33292093 | ||
| A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease | Q33292510 | ||
| A portrait of Alzheimer secretases--new features and familiar faces | Q34345559 | ||
| Adjuvants for human vaccines--current status, problems and future prospects | Q34373525 | ||
| Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. | Q34417339 | ||
| Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid | Q34698382 | ||
| Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology | Q34763076 | ||
| Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning | Q34932593 | ||
| Does my mouse have Alzheimer's disease? | Q35186500 | ||
| Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. | Q35841991 | ||
| Cytokine regulation of immunoglobulin isotype switching and expression. | Q35999290 | ||
| Lymphokine control of in vivo immunoglobulin isotype selection. | Q36576188 | ||
| Amyloid Protein and Alzheimer's Disease | Q36938484 | ||
| Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease | Q37118356 | ||
| Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma | Q40694541 | ||
| Alzheimer's disease: a central role for amyloid | Q40701623 | ||
| Cellular and molecular biology of Alzheimer's disease and animal models | Q40759701 | ||
| Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease | Q41753192 | ||
| Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease | Q43860008 | ||
| Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. | Q44132564 | ||
| Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias | Q44419196 | ||
| Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome | Q45007178 | ||
| Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide | Q45295828 | ||
| Unusual spectral energy distribution of a galaxy previously reported to be at redshift 6.68. | Q46011081 | ||
| A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease | Q47583762 | ||
| Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. | Q47904576 | ||
| Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease | Q48007049 | ||
| Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease | Q48300537 | ||
| Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. | Q48363055 | ||
| Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. | Q48396310 | ||
| Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies | Q48797820 | ||
| Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. | Q48893777 | ||
| Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo | Q48925662 | ||
| Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes | Q52088160 | ||
| Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. | Q52112638 | ||
| Set back to Alzheimer vaccine studies. | Q53246987 | ||
| Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD | Q58005269 | ||
| Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a | Q61853750 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| antibody | Q79460 | ||
| vaccine | Q134808 | ||
| infectious disease | Q18123741 | ||
| P304 | page(s) | 2275-2282 | |
| P577 | publication date | 2005-12-05 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch | |
| P478 | volume | 24 |
| Q36326816 | A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders |
| Q28740910 | A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques |
| Q35040016 | A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory |
| Q37435886 | Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease |
| Q37625591 | Adjuvants and autoimmunity |
| Q37438255 | Alternative Abeta immunotherapy approaches for Alzheimer's disease |
| Q33935251 | Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. |
| Q53318106 | Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease. |
| Q33954737 | Amyloid-beta immunotherapy for Alzheimer's disease |
| Q36677402 | An update on pharmacological approaches to neurodegenerative diseases |
| Q27024202 | CD4 T cells in immunity and immunotherapy of Alzheimer's disease |
| Q80633269 | Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study |
| Q45300233 | Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease |
| Q42610772 | Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide |
| Q33957114 | DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. |
| Q37086973 | DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype |
| Q33647708 | DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. |
| Q36607324 | Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there? |
| Q36026890 | Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease |
| Q50776088 | Identification and mapping of linear antigenic determinants of human amyloid ß(1-42) peptide. |
| Q37209757 | Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment |
| Q24599108 | Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease |
| Q38187861 | Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines |
| Q36790089 | Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial |
| Q37634138 | Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. |
| Q22241491 | Immunotherapy as treatment for Alzheimer’s disease |
| Q48603497 | In vivo electroporation of a new gene vaccine encoding ten repeats of Aβ3-10 prevents brain Aβ deposition and delays cognitive impairment in young Tg-APPswe/PSEN1dE9 mice |
| Q41983452 | MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice |
| Q34624985 | Oral administration of a fusion protein between the cholera toxin B subunit and the 42-amino acid isoform of amyloid-β peptide produced in silkworm pupae protects against Alzheimer's disease in mice |
| Q37438261 | Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy |
| Q33332164 | Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy |
| Q37672845 | T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers |
| Q36558485 | Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies |
| Q54941797 | The antibody response in the bovine mammary gland is influenced by the adjuvant and the site of subcutaneous vaccination. |
| Q35183183 | The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease |
| Q37896029 | The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease. |
| Q49138161 | The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. |
| Q37842339 | Therapeutic potential of vaccines for Alzheimer's disease |
| Q35844472 | Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage |
| Q42655652 | UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease |
| Q38567072 | Vaccines, adjuvants and autoimmunity |
Search more.